Fused heterocyclic compounds as ion channel modulators

Patent metadata

Field	Value
Publication number	US-9416115-B2
Application number	US-201414559011-A
Country	US
Kind code	B2
Filing date	Dec 3, 2014
Priority date	Dec 20, 2013
Publication date	Aug 16, 2016
Grant date	Aug 16, 2016

Abstract

The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I:

wherein X, Y, Z, R 2 , R 3 , R 4 , p and q are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

First claim

What is claimed is:

1. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt, stereoisomer or mixture of stereoisomer thereof.

2. A compound selected from the group consisting of:

3. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt, thereof.

4. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of the compound of claim 2 or a pharmaceutically acceptable salt, thereof.

Assignees

• Gilead Sciences Inc
• Gilead Scineces Inc

Inventors

• Graupe Michael
• Lu Yafan
• Zablocki Jeff A

Classifications

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title